Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
14:07 ET -- Merck is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. After the bell Thursday, Merck and Daiichi Sankyo announced a global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs. On Friday, Merck released data showing its Keytruda in combination with other treatments showed statistically significant improvement in pathological complete response rate for certain breast cancer patients, and that it improved progression-free survival in certain patients with cervical cancer. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
October 20, 2023 14:22 ET (18:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase
-
After Earnings, Is Nio Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Lululemon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks